Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched …

GS Nowakowski, DH Yoon, A Peters, P Mondello… - Clinical Cancer …, 2022 - AACR
Purpose: In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study
(NCT02399085) of tafasitamab plus lenalidomide were retrospectively compared with …

Target estimands for population-adjusted indirect comparisons

A Remiro-Azócar - arXiv preprint arXiv:2112.08023, 2021 - arxiv.org
Disagreement remains on what the target estimand should be for population-adjusted
indirect treatment comparisons. This debate is of central importance for policy-makers and …

[HTML][HTML] Model-based standardization using multiple imputation

A Remiro-Azócar, A Heath, G Baio - BMC Medical Research Methodology, 2024 - Springer
Background When studying the association between treatment and a clinical outcome, a
parametric multivariable model of the conditional outcome expectation is often used to …

Combining real-world and randomized control trial data using data-adaptive weighting via the on-trial score

J Harton, B Segal, R Mamtani, N Mitra… - Statistics in …, 2023 - Taylor & Francis
Clinical trials with a hybrid control arm (a control arm constructed from a combination of
randomized patients and real-world data on patients receiving usual care in standard …

[HTML][HTML] Approaches for enhanced extrapolation of long-term survival outcomes using electronic health records of patients with cancer

X Wang, BJ Adamson, A Briggs, K Tan, D Bargo… - Value in Health, 2022 - Elsevier
Objectives This study aimed to demonstrate enhanced survival extrapolation methods using
electronic health record-derived real-world data (RWD). Methods The study population …

Population-adjusted indirect treatment comparisons with limited access to patient-level data

A Remiro Azócar - 2022 - discovery.ucl.ac.uk
Health technology assessment systems base their decision-making on health-economic
evaluations. These require accurate relative treatment effect estimates for specific patient …

[PDF][PDF] Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors

P Gaitonde, V Chirikov, S Kelkar… - Cancer Management and …, 2022 - Taylor & Francis
Background To extend the discussion on the use of real-world evidence (RWE) in conveying
the clinical value of treatment beyond trial data, the primary objective of this study was to …

Integrating real world data and clinical trial results using survival data reconstruction and marginal moment-balancing weights

K Getz, R Mamtani, RA Hubbard - Journal of biopharmaceutical …, 2022 - Taylor & Francis
Outcomes in electronic health records (EHR)-derived cohorts can be compared to similarly
treated clinical trial cohorts to estimate the efficacy-effectiveness gap, the discrepancy in …

Methods for Comparative Effectiveness Research with Real World Data

JG Harton - 2022 - search.proquest.com
Electronic health records (EHR) contain a wealth of information that can potentially be used
for research. EHR is particularly valuable for accelerating comparative effectiveness …

Real-World Evidence Generation

JS Imperato, JP Cook, D Morgenstern… - … -World Evidence in …, 2022 - api.taylorfrancis.com
Healthcare facilities routinely collect medical and patient data and electronically record them
when patients use their facilities. Measurements of blood pressure, prescribed medications …